MTOR and hepatocellular carcinoma: Alternatively, recent investigations demonstrated that some of the miRNA members in C19MC were upregulated in hepatocellular carcinoma characterized by aberrant IGF, phosphatidylinositol 3 kinase (PI3K)-Akt-mTOR or p53 pathway activation [23], [24].